Publications en collaboration avec des chercheurs de Centro de Investigación Médica Aplicada (65)

2024

  1. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

2023

  1. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation

    Blood, Vol. 141, Núm. 9, pp. 1047-1059

  2. Chronic docosahexaenoic acid supplementation improves metabolic plasticity in subcutaneous adipose tissue of aged obese female mice

    Journal of Nutritional Biochemistry, Vol. 111

  3. Differential remodeling of subcutaneous white and interscapular brown adipose tissue by long-term exercise training in aged obese female mice

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 2, pp. 451-465

  4. Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance

    Nature Communications, Vol. 14, Núm. 1

  5. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

  6. Targeting the immune microenvironment in Waldenström macroglobulinemia via halting the CD40/CD40-ligand axis

    Blood, Vol. 141, Núm. 21, pp. 2615-2628

  7. Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- And high-risk myeloma

    Blood, Vol. 137, Núm. 1, pp. 49-60

  2. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

2020

  1. B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation

    Leukemia, Vol. 34, Núm. 4, pp. 1158-1162

  2. Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL

    Leukemia, Vol. 34, Núm. 10, pp. 2722-2735

2019

  1. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  2. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6546-6573

  2. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy

    Journal of Medicinal Chemistry, Vol. 61, Núm. 15, pp. 6518-6545

  3. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

  4. Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in b lymphoid neoplasms

    Haematologica, Vol. 103, Núm. 6, pp. 1065-1072

2017

  1. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

    Nature Communications, Vol. 8